Federal authorities have announced a $24 million civil fraud settlement involving a Dallas laboratory and certain owners and investors over alleged misconduct tied to COVID-19 testing. The resolution is a notable reminder that pandemic-era billing practices remain a live enforcement priority, especially where the government believes testing claims were inflated, medically unnecessary, or otherwise noncompliant.

Although the matter was resolved through settlement rather than a litigated judgment, the size of the payment underscores how aggressively the Department of Justice continues to use civil fraud tools in the healthcare space.

The Justice Department’s Antitrust Division has announced a criminal indictment against four container manufacturing companies and seven executives for an alleged price-fixing conspiracy during the Covid-19 pandemic. Even without all charging details yet public, the case stands out for pairing corporate defendants with individual executive charges in a market tied to essential goods during a period of severe supply-chain disruption.

That combination is important.